Acelyrin Shares Skyrocket Following Encouraging Phase 1/2 Trial Results

Wednesday, 20 March 2024, 14:09

Acelyrin (SLRN) experiences a significant uptick in share value as a result of the promising Phase 1/2 trial data regarding lonigutamab's effectiveness in treating thyroid eye disease. The data indicates potential for sustained positive outcomes with subcutaneous dosing over an extended period.

https://store.livarava.com/15fc4b92-e73d-11ee-968e-5254a2021b2b.jpe — Acelyrin Shares Skyrocket Following Encouraging Phase 1/2 Trial Results

Acelyrin Shares Rise on Positive Trial Data

Acelyrin (SLRN) witnessed a surge in its stock price following the release of encouraging Phase 1/2 trial results for lonigutamab, a drug targeted at treating thyroid eye disease. The trial highlights the effectiveness of lonigutamab, especially when administered through subcutaneous injections using a longer-term treatment approach.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.